I pick out North America’s celestial highlights for the week ahead (which also applies to northern hemisphere mid-northern latitudes).
Venus Remedies is collaborating with UK-based Infex Therapeutics for the clinical development of MET-X, a metallo-beta-lactamase (MBL) inhibitor that helps reduce resistance to beta-lactam antibiotics such as meropenem.
"This early-stage introduction of MET-X into the Indian market leverages our decades-long dedication to AMR-focused R&D and our prominent role in critical care and antibiotic ther
Publisher Koei Tecmo and developer Team NINJA have released a new trailer, information, and screenshots for Venus Vacation PRISM: DEAD OR ALIVE Xtreme, introducing the collaboration episodes with
The agreement authorises Venus Remedies to spearhead the clinical development, registration, and commercialisation of MET-X, an innovative metallo-beta- lactamase (MBL) inhibitor
The deal grants Venus Remedies the rights to develop, register, and commercialise MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, in India. Currently, there are no approved MBL inhibitors available in the country.
Venus Remedies has partnered with Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, to tackle drug-resistant gram-negative bacteria in India. The partnership aims to address the growing concern of antibiotic resistance and provide effective treatment options for patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results